Lanier Pharma Probe Targets Bogus Vancocin CDAD Treatment Pricing Scheme
Americans who rely on Vancocin HCI capsules to treat C. difficile-associated diarrhea, or CDAD, have been paying artificially inflated prices for this drug. According to FTC investigators, drug maker Shire ViroPharma Inc. has embraced an illegal scheme to flood the U.S. Food and Drug Administration with bogus filings and lawsuits in an effort to delay the FDA from allowing lower-cost generics from entering the market.
ViroPharma’s stalling tactics have delayed the rollout of cheaper generic alternatives for more than six years, according to the FTC. In the meantime, the company has raised prices steadily. As a result, consumers who rely on the drug have paid hundreds of millions of dollars more than necessary, according to the FTC. The company’s revenue from Vancocin sales increased 650 percent between 2004 and 2011.
The Vancocin antibiotic (vancomycin hydrochloride) is often used to treat potentially deadly diarrhea associated with Clostridium difficile infections.
“ViroPharma’s repetitive, serial, and meritless petitioning harmed competition and consumer welfare by obstructing and delaying the FDA approval process for a generic version,” argues the lawsuit. “Each time the FDA was close to finalizing its response to ViroPharma’s filings and contemporaneously approving generic Vancocin Capsules, ViroPharma would submit another filing, often raising issues that ViroPharma itself doubted or that it could have raised earlier and/or repeating issues raised earlier.”
While the FTC continues to investigate wrongdoing by ViroPharma, The Lanier Law Firm is representing consumers who have suffered as a result of these anti-competitive practices.
Please contact us for more information by filling out the form on this page.